European Commission approves Onureg for certain AML subtypes

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The European Commission has approved Onureg (azacitidine tablets)as the first and only once-daily, frontline oral maintenance therapy in the EU for patients with a broad range of acute myeloid leukemia subtypes. 

While many patients with AML achieve remission with induction therapy, about 50% of patients relapse within one year. In the pivotal QUAZAR AML-001 study, Onureg significantly improved overall survival and relapse-free survival in patients with AML, reinforcing its clinical benefit and role in the treatment paradigm for patients with this common acute leukemia.

Onureg is sponsored by Bristol Myers Squibb.

Table of Contents

YOU MAY BE INTERESTED IN

Twenty years ago, the discovery of epidermal growth factor receptor mutations as drivers of tumorigenesis and viable targets for therapeutic intervention marked the beginning of a new era in lung cancer diagnosis and treatment. Since then, the field has made remarkable progress towards developing more effective targeted treatments and immunotherapies that have significantly improved patient outcomes and survival.

Login